Michaela A Dinan1, Xiaojuan Mi2, Shelby D Reed1, Bradford R Hirsch1, Gary H Lyman3, Lesley H Curtis4. 1. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina2Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina3Department of Medicine, Duke University School of Medicine, Durham, North Caroli. 2. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. 3. Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences Division and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington5Division of Medical Oncology, Department of Medicine, University of Washington S. 4. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina3Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
Abstract
IMPORTANCE: In 2006, the Centers for Medicare & Medicaid Services approved coverage for the use of the 21-gene recurrence score (RS) assay in women with early-stage, estrogen receptor-positive, node-negative breast cancers to help guide recommendations for adjuvant chemotherapy. Use of the assay in community settings has not been previously examined in a nationally representative sample of patients. OBJECTIVE: To examine trends in the use of the RS assay in routine clinical practice in a nationally representative sample of women with breast cancer. DESIGN, SETTING, AND PARTICIPANTS: Retrospective observational study of Medicare beneficiaries diagnosed with incident breast cancer between 2005 and 2009, as recorded in a Surveillance, Epidemiology, and End Results data set with linked Medicare claims through 2010. MAIN OUTCOMES AND MEASURES: Demographic and clinical variables associated with the use of the assay. RESULTS: A total of 70,802 patients met the study criteria. Use of the RS assay increased from 1.1% in 2005 to 10.1% in 2009 (P < .001). The majority of tests (60.9%) occurred in patients with National Comprehensive Cancer Network-defined intermediate-risk disease (ie, estrogen receptor-positive, node-negative tumors >1 cm). Most patients with other than intermediate-risk disease had borderline indications for testing, including T1b (47.5%) or N1 (26.8%) disease. Testing was associated with younger age, fewer comorbid conditions, higher-grade disease, and being married. Among patients younger than 70 years with intermediate-risk disease, testing rates increased from 7.7% in 2005 to 38.8% in 2009 (P < .001). In multivariable analysis, testing was modestly higher in Northeast than in Western registries (odds ratio, 1.83; 95% CI, 1.49-2.26) but was otherwise not associated with region, local census tract demographic characteristics, black race, location in an urban area, or tumor histologic characteristics. CONCLUSIONS AND RELEVANCE: The RS assay was adopted quickly in clinical practice after the Medicare coverage decision in 2006, and use appears to be consistent with guidelines and equitable across geographic and racial groups. Factors influencing adoption of the assay and its impact on adjuvant chemotherapy use in clinical practice remain important areas of study.
IMPORTANCE: In 2006, the Centers for Medicare & Medicaid Services approved coverage for the use of the 21-gene recurrence score (RS) assay in women with early-stage, estrogen receptor-positive, node-negative breast cancers to help guide recommendations for adjuvant chemotherapy. Use of the assay in community settings has not been previously examined in a nationally representative sample of patients. OBJECTIVE: To examine trends in the use of the RS assay in routine clinical practice in a nationally representative sample of women with breast cancer. DESIGN, SETTING, AND PARTICIPANTS: Retrospective observational study of Medicare beneficiaries diagnosed with incident breast cancer between 2005 and 2009, as recorded in a Surveillance, Epidemiology, and End Results data set with linked Medicare claims through 2010. MAIN OUTCOMES AND MEASURES: Demographic and clinical variables associated with the use of the assay. RESULTS: A total of 70,802 patients met the study criteria. Use of the RS assay increased from 1.1% in 2005 to 10.1% in 2009 (P < .001). The majority of tests (60.9%) occurred in patients with National Comprehensive Cancer Network-defined intermediate-risk disease (ie, estrogen receptor-positive, node-negative tumors >1 cm). Most patients with other than intermediate-risk disease had borderline indications for testing, including T1b (47.5%) or N1 (26.8%) disease. Testing was associated with younger age, fewer comorbid conditions, higher-grade disease, and being married. Among patients younger than 70 years with intermediate-risk disease, testing rates increased from 7.7% in 2005 to 38.8% in 2009 (P < .001). In multivariable analysis, testing was modestly higher in Northeast than in Western registries (odds ratio, 1.83; 95% CI, 1.49-2.26) but was otherwise not associated with region, local census tract demographic characteristics, black race, location in an urban area, or tumor histologic characteristics. CONCLUSIONS AND RELEVANCE: The RS assay was adopted quickly in clinical practice after the Medicare coverage decision in 2006, and use appears to be consistent with guidelines and equitable across geographic and racial groups. Factors influencing adoption of the assay and its impact on adjuvant chemotherapy use in clinical practice remain important areas of study.
Authors: Chalanda N Evans; Noel T Brewer; Susan T Vadaparampil; Marc Boisvert; Yvonne Ottaviano; M Catherine Lee; Claudine Isaacs; Marc D Schwartz; Suzanne C O'Neill Journal: Breast Cancer Res Treat Date: 2016-04-08 Impact factor: 4.872
Authors: Suzanne C O'Neill; Kathryn L Taylor; Jonathan Clapp; Jinani Jayasekera; Claudine Isaacs; Deena Mary Atieh Graham; Stuart L Goldberg; Jeanne Mandelblatt Journal: J Health Commun Date: 2018-08-21
Authors: Allison W Kurian; Irina Bondarenko; Reshma Jagsi; Christopher R Friese; M Chandler McLeod; Sarah T Hawley; Ann S Hamilton; Kevin C Ward; Timothy P Hofer; Steven J Katz Journal: J Natl Cancer Inst Date: 2018-05-01 Impact factor: 13.506
Authors: Hannah Y Wen; Melissa Krystel-Whittemore; Sujata Patil; Fresia Pareja; Zenica L Bowser; Maura N Dickler; Larry Norton; Monica Morrow; Clifford A Hudis; Edi Brogi Journal: Cancer Date: 2016-08-15 Impact factor: 6.860
Authors: Megan C Roberts; Morris Weinberger; Stacie B Dusetzina; Michaela A Dinan; Katherine E Reeder-Hayes; Lisa A Carey; Melissa A Troester; Stephanie B Wheeler Journal: J Clin Oncol Date: 2015-11-23 Impact factor: 44.544
Authors: Kelsey E Larson; Stephanie A Valente; Chirag Shah; Rahul D Tendulkar; Sheen Cherian; Jame Abraham; Courtney Yanda; Chao Tu; Jessica Echle; Stephen R Grobmyer Journal: Mol Clin Oncol Date: 2018-08-23
Authors: Andreana N Holowatyj; Michele L Cote; Julie J Ruterbusch; Kristina Ghanem; Ann G Schwartz; Fawn D Vigneau; David H Gorski; Kristen S Purrington Journal: J Clin Oncol Date: 2018-01-17 Impact factor: 44.544